Impact of Hormone Replacement Therapy on Breast Cancer Risk Following Oophorectomy in Women with BRCA Pathogenic Variants

1

Women with BRCA1 and BRCA2 pathogenic variants face a high lifetime risk of breast and ovarian cancers.
2

Risk-reducing bilateral salpingo-oophorectomy significantly lowers all-cause mortality in women with BRCA pathogenic variants.
3

Hormone replacement therapy is often considered post-oophorectomy to alleviate early menopause symptoms and improve quality of life.
4

Estrogen-only hormone replacement therapy does not increase breast cancer risk, while combined estrogen-progestin regimens may elevate risk.
5

The study aims to clarify the association between hormone replacement therapy and breast cancer incidence in women after oophorectomy.

Jama Network Open

by Shira Regev-Sadeh, Rachel Michaelson-Cohen, Dana Madorksy-Feldman, Eitan Friedman, Shunit Armon, Amalfi Qarawani, Naama Srebnik, Joul Haddad, Vered H. Eisenberg, Yakir Segev
April 8, 2026

1